USE OF ANTIGEN Кі-67 IN BASAL-LIKE BREAST CANCER DIAGNOSTICS IN THE CONDITIONS OF LARGE INDUSTRIAL REGION OF SOUTHEAST OF UKRAINE

  • T. Yu. Pogorila ZAPORIZHZHIA MEDICAL ACADEMY OF POSTGRADUATE EDUCATION
  • S. M. Pashchenko ZAPORIZHZHIA MEDICAL ACADEMY OF POSTGRADUATE EDUCATION
  • M. S. Shchurov ZAPORIZHZHIA MEDICAL ACADEMY OF POSTGRADUATE EDUCATION
Keywords: basal-like breast cancer, antigen Ki-67 expression

Abstract

Introduction. Аlong all molecular genetic types of breast cancer, basal-like tumors account 10–24 %. To carry out more proficient monitoring different biological markers that allow detecting the most aggressive tumors were revealed and applied in practice. One of such markers is Ki-67.

The aim of the study – to learn Ki-67 expression in basal-like breast cancers in the conditions of large industrial region of southeast of Ukraine.

Research Methods. Immunohistological researches were held among patients, living in a large industrial place in south-eastern Ukraine. For all patients (150 persons) with basal-like form of mammary gland and for patients with other molecular-genetic forms (40 persons) of cancer of mammary gland analysed the level of expression (by B. Risberg of et al.) of antigen of Кі-67.

Results and Discussion. The results of immunohistochemical studies of patients with breast cancer were analyzed, in particular, according to the degree of expression of the Ki-67 proliferation marker, depending on the place of residence. A tendency was established to increase the expression of the Ki-67 proliferation marker when evaluating patients living in different areas of Zaporizhzhia (from environmentally friendly to areas that are close to large industrial sites). The Ki-67 proliferation marker was determined in all 150 patients with breast cancer with different expression levels. In a group of patients (40 individuals) with other molecular genetic types of breast cancer, the expression of Ki-67 was detected in 24 (60.0 %) cases; in 16 (40.0 %) cases, expression of the Ki-67 proliferation marker was not determined; a high level of expression of Ki-67 was determined in 2.5 % of patients in this group.

Conclusions. It is set features of motion of basal-like breast cancer from the presence of Ki-67. Frequency of origin of basal-like breast cancer rises on 41–44 % for patients, that live in boroughs of Zaporizhzhia, near to the industrial grounds. These patients look after the increase of expression of marker of proliferative of Ki – 67 on 45 %. Patients with a low level of Ki-67 expression (0–15%) live twice as long as patients with breast cancer with a high level (>50 %) of Ki-67 expression. In patients with breast cancer with low expression of Ki-67 (according to the Risberg classification), overall survival reaches 25 months or more. It was determined that the metastasis of patients with basal-like breast cancer depends on the level of expression of the proliferation marker. At a proliferation marker expression level of 51–100 %, metastasis was detected in 56.80 %. The frequency of relapses in patients with breast cancer is associated with the expression level of the proliferation marker Ki-67. The relapse rate in groups where Ki-67 expression reached 26–50 % and 51–100 % is 7.40 % and 22.22 %, respectively.

References

С.А. Тюляндин и авт. Тройной негативный рак молочной железы / С.А. Тюляндин, M.Б. Стенина, М.А. Фролова // Фундаментальные исследования. – 2013. – № 9 (часть 5) – С. 881-885// Практическая Онкология-Т.11, №4–с.247-251-2010.

Глузман (2010) Факторы риска развития местных рецидивов инвазивного рака грудной железы. Онкология, 4(12): 347–350.

Щепотин И.Б., Зотов А.С., Любота И.И., Любота Р.В., Зайчук В.В., Захарцева Л.М. (2010) Факторы риска развития местных рецидивов инвазивного рака грудной железы. Онкология, 4(12): 347–350.

Perou C.M., Sorlie T., Eisen M.B. et al. (2000) Molecular portraits of human breast tumours. Nature, 406: 747–752.

Prat A., Perou C.M. 2009.- Mammary development meets cancer genomics. Nat Med., 15: р.842–844.

Rakha EA, El-Rehim DA, Paish C, et al. Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer 2006.- 42: р.3149–3156.PubMedView Article.

Семиглазов В.Ф. Стратегия лечения рака молочной железы, основанная на выделении биологических подтипов. «Вопросы онкологии». 2011. - с.52-542.

Published
2019-11-07
How to Cite
Pogorila, T. Y., Pashchenko, S. M., & Shchurov, M. S. (2019). USE OF ANTIGEN Кі-67 IN BASAL-LIKE BREAST CANCER DIAGNOSTICS IN THE CONDITIONS OF LARGE INDUSTRIAL REGION OF SOUTHEAST OF UKRAINE. Medical and Clinical Chemistry, (3), 23-27. https://doi.org/10.11603/mcch.2410-681X.2019.v.i3.10389
Section
ORIGINAL INVESTIGATIONS